A — yes. Evidence from multiple studies shows that elevated fecal calprotectin levels in patients with quiescent inflammatory bowel disease are associated with a higher likelihood of clinical relapse, supporting its use as a predictive biomarker [Tibble, 2000, PMID: 10716687; Gisbert, 2014, PMID: 24487554].